OSR (NASDAQ:OSRH – Get Free Report) and CureVac (NASDAQ:CVAC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
55.3% of OSR shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 2.1% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
OSR has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares OSR and CureVac’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | -593.15% | -8.36% | -6.24% |
| CureVac | 199.92% | -23.03% | -19.09% |
Valuation & Earnings
This table compares OSR and CureVac”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OSR | $1.81 million | 3.92 | -$27.06 million | ($0.37) | -0.55 |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
CureVac has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Summary
CureVac beats OSR on 7 of the 11 factors compared between the two stocks.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
